These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 11938683)
1. [Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene]. Spinelli C; Puccini M; Bertocchini A; Lima M; Pacini F; Miccoli P Pediatr Med Chir; 2002; 24(1):53-7. PubMed ID: 11938683 [TBL] [Abstract][Full Text] [Related]
2. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Wells SA; Skinner MA Exp Clin Endocrinol Diabetes; 1998; 106(1):29-34. PubMed ID: 9516056 [TBL] [Abstract][Full Text] [Related]
5. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265 [TBL] [Abstract][Full Text] [Related]
6. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. Frank-Raue K; Raue F Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387 [TBL] [Abstract][Full Text] [Related]
7. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Frilling A; Dralle H; Eng C; Raue F; Broelsch CE Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529 [TBL] [Abstract][Full Text] [Related]
8. [Medullary thyroid gland carcinoma. Sporadic/familial. Screening when and why?]. Frilling A; Liedke MO Internist (Berl); 1998 Jun; 39(6):588-91. PubMed ID: 9677514 [No Abstract] [Full Text] [Related]
9. Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2. Frilling A; Höppner W; Eng C; Mulligan L; Raue F; Broelsch CE J Mol Med (Berl); 1995 May; 73(5):229-33. PubMed ID: 7670926 [TBL] [Abstract][Full Text] [Related]
10. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662 [TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. Skinner MA; DeBenedetti MK; Moley JF; Norton JA; Wells SA J Pediatr Surg; 1996 Jan; 31(1):177-81; discussion 181-2. PubMed ID: 8632274 [TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Raue F; Frank-Raue K Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918 [TBL] [Abstract][Full Text] [Related]
13. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene]. Fitze G; Saeger HD; Roesner D; Schackert HK Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293 [TBL] [Abstract][Full Text] [Related]
14. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. Moore SW; Appfelstaedt J; Zaahl MG J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Kambouris M; Jackson CE; Feldman GL Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338 [TBL] [Abstract][Full Text] [Related]
16. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature]. de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023 [TBL] [Abstract][Full Text] [Related]
17. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers]. Sansó G; Domené HM; Iorcansky S; Barontini M Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252 [TBL] [Abstract][Full Text] [Related]
18. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251 [TBL] [Abstract][Full Text] [Related]
19. [Somatic ret proto-oncogene mutations in sporadic C-cell carcinoma of the thyroid gland]. Frilling A; Bockhorn M; Kalinin V; Liedke M; Kaun M; Broelsch CE Chirurg; 1997 Aug; 68(8):789-93. PubMed ID: 9377989 [TBL] [Abstract][Full Text] [Related]
20. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]